LEADER 03968nam  22006734a 450 
001 9910970994503321
005 20251017110141.0
010   $a9786612083914
010   $a9780309182744
010   $a0309182743
010   $a9781282083912
010   $a1282083910
010   $a9780309557849
010   $a0309557844
010   $a9780309528894
010   $a0309528895
035   $a(CKB)111069351126410
035   $a(EBL)3375213
035   $a(SSID)ssj0000104048
035   $a(PQKBManifestationID)11122675
035   $a(PQKBTitleCode)TC0000104048
035   $a(PQKBWorkID)10078613
035   $a(PQKB)11107650
035   $a(MiAaPQ)EBC3375213
035   $a(Au-PeEL)EBL3375213
035   $a(CaPaEBR)ebr10032410
035   $a(OCoLC)923255147
035   $a(Perlego)4739136
035   $a(DNLM)1148366
035   $a(BIP)7650717
035   $a(EXLCZ)99111069351126410
100   $a20020325d2002      uy         0
101 0 $aeng
135   $aurcn|||||||||
181   $ctxt
182   $cc
183   $acr
200 04$aThe anthrax vaccine $eis it safe? does it work? /$fLois M. Joellenbeck ... [et al.], editors ; Committee to Assess the Safety and Efficacy of the Anthrax Vaccine, Medical Follow-up Agency, Institute of Medicine
205   $a1st ed.
210   $aWashington, D.C. $cNational Academy Press$dc2002
215   $a1 online resource (288 p.)
300   $aDescription based upon print version of record.
311 08$a9780309083096 
311 08$a0309083095 
320   $aIncludes bibliographical references.
327   $a""Front Matter""; ""Preface""; ""Acknowledgments""; ""Reviewers""; ""Contents""; ""Figures, Tables, and Boxes""; ""Abbreviations and Acronyms""; ""Executive Summary""; ""1 Introduction""; ""2 Background""; ""3 Anthrax Vaccine Efficacy""; ""4 Safety: Introduction""; ""5 Safety: Case Reports""; ""6 Safety: Epidemiologic Studies""; ""7 Anthrax Vaccine Manufacture""; ""8 Future Needs""; ""Appendix A Statement of Task""; ""Appendix B Biographical Sketches""; ""Appendix C Information-Gathering Meeting Agendas""; ""Appendix D Anthrax Vaccine Adsorbed Package Inserts""
327   $a""Appendix E Vaccine Adverse Event Reporting System (VAERS) Form""""Appendix F Anthrax Vaccine Expert Committee (AVEC) Case Assessment Form""; ""Appendix G DMSS Analyses Requested by the IOM Committee to Assess the Safety and Efficacy of the Anthrax Vaccine""; ""An Assessment of the Safety of the Anthrax Vaccine A Letter Report Appendix H""
330   $aThe vaccine used to protect humans against the anthrax disease, called Anthrax Vaccine Adsorbed (AVA), was licensed in 1970. It was initially used to protect people who might be exposed to anthrax where they worked, such as veterinarians and textile plant workers who process animal hair. When the U. S. military began to administer the vaccine, then extended a plan for the mandatory vaccination of all U. S. service members, some raised concerns about the safety and efficacy of AVA and the manufacture of the vaccine. In response to these and other concerns, Congress directed the Department of Defense to support an independent examination of AVA.  The Anthrax Vaccine: Is It Safe? Does It Work? reports the study (TM)s conclusion that the vaccine is acceptably safe and effective in protecting humans against anthrax. The book also includes a description of advances needed in main areas: improving the way the vaccine is now used, expanding surveillance efforts to detect side effects from its use, and developing a better vaccine.
606   $aAnthrax$xVaccination
615  0$aAnthrax$xVaccination.
676   $a614.5/61
712 02$aInstitute of Medicine (U.S.).$bCommittee to Assess the Safety and Efficacy of the Anthrax Vaccine.
801  0$bMiAaPQ
801  1$bMiAaPQ
801  2$bMiAaPQ
906   $aBOOK
912   $a9910970994503321
996   $aThe anthrax vaccine$94354082
997   $aUNINA